120 related articles for article (PubMed ID: 15735242)
1. Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance.
DeLong M; Logan JL; Yong KC; Lien YH
Nephrol Dial Transplant; 2005 Mar; 20(3):585-90. PubMed ID: 15735242
[TBL] [Abstract][Full Text] [Related]
2. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients.
Lin HH; Yang YF; Chang JK; Ting IW; Kuo HL; Wang IK; Huang CC
Ren Fail; 2009; 31(10):942-5. PubMed ID: 20030530
[TBL] [Abstract][Full Text] [Related]
4. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis.
Schwenk MH; Jumani AQ; Rosenberg CR; Kulogowski JE; Charytan C; Spinowitz BS
Pharmacotherapy; 1998; 18(3):627-30. PubMed ID: 9620114
[TBL] [Abstract][Full Text] [Related]
5. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
6. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?
Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
Nephrology (Carlton); 2006 Oct; 11(5):394-9. PubMed ID: 17014551
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
8. Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status.
Di Iorio BR; Stellato D; De Santo NG; Cirillo M;
Blood Purif; 2004; 22(5):423-7. PubMed ID: 15316197
[TBL] [Abstract][Full Text] [Related]
9. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
[TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan.
Tang CH; Chen TH; Wang CC; Hong CY; Huang KC; Sue YM
Eur J Heart Fail; 2013 Oct; 15(10):1194-202. PubMed ID: 23671265
[TBL] [Abstract][Full Text] [Related]
11. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
12. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
[TBL] [Abstract][Full Text] [Related]
13. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients.
Messa P; Nicolini MA; Cesana B; Brezzi B; Zattera T; Magnasco A; Moroni G; Campise M
Nephrol Dial Transplant; 2006 Feb; 21(2):431-6. PubMed ID: 16249199
[TBL] [Abstract][Full Text] [Related]
14. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
Onuigbo MA; Onuigbo NT
QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
[TBL] [Abstract][Full Text] [Related]
15. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.
Furumatsu Y; Nagasawa Y; Hamano T; Iwatani H; Iio K; Shoji T; Ito T; Tsubakihara Y; Imai E
Nephrol Dial Transplant; 2008 Mar; 23(3):984-90. PubMed ID: 17956890
[TBL] [Abstract][Full Text] [Related]
16. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.
Locatelli F; Andrulli S; Memoli B; Maffei C; Del Vecchio L; Aterini S; De Simone W; Mandalari A; Brunori G; Amato M; Cianciaruso B; Zoccali C
Nephrol Dial Transplant; 2006 Apr; 21(4):991-8. PubMed ID: 16384825
[TBL] [Abstract][Full Text] [Related]
17. [Effect of angiotensin-converting enzyme inhibitors on serum levels of erythropoietin in patients on peritoneal dialysis].
Huang YH
Di Yi Jun Yi Da Xue Xue Bao; 2002 Jan; 22(1):74-5. PubMed ID: 12390854
[TBL] [Abstract][Full Text] [Related]
18. Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian study.
Pajek J; Bucar-Pajek M; Grego K; Gucek A; Bevc S; Ekart R; Vujkovac B; Golob-Kosmina P; Kandus A; Bren AF
Ther Apher Dial; 2005 Jun; 9(3):228-32. PubMed ID: 15966995
[TBL] [Abstract][Full Text] [Related]
19. Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients.
Chan KE; Lafayette RA; Whittemore AS; Hlatky MA; Moran J
Nephrol Dial Transplant; 2008 Sep; 23(9):2948-56. PubMed ID: 18469314
[TBL] [Abstract][Full Text] [Related]
20. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
